C. H. Robinson Worldwide stock gets mixed targets after RXO deal

C. H. Robinson Worldwide stock (ISIN US12541W2098) is being reassessed after analyst targets diverged following the RXO transaction, with recent targets spanning USD 151 to USD 230. The company also delivered Q2 2026 revenue of USD 4.93 billion, up 19.3 percent year over year, according to MarketBeat.

Analysts split after RXO deal

The clearest short-term divide is visible in target changes. According to Investing.com on October 6, 2026, BofA Securities cut its target from USD 226 to USD 203 while retaining a Buy rating. UBS took the opposite tone, reiterating Buy with a USD 230 target, according to Investing.com on October 6, 2026.

The consensus remains constructive but leaves a wide valuation gap. MarketBeat reports a Moderate Buy rating from 25 brokerages and an average target of USD 196.64. That average lies 45.5 percent above the USD 135.18 Nasdaq price on October 7, 2026.

RXO adds scale and financing risk

The October 5, 2026 filing sets the transaction value at USD 5.8 billion and says C. H. Robinson expects USD 300 million in net run-rate cost synergies within two years after closing. The deal is expected to close in the first half of 2027, subject to regulatory and shareholder approvals, according to StockTitan.

The filing also describes a bridge facility of up to USD 4.5 billion and a planned consideration mix of 57 percent cash and 43 percent C. H. Robinson shares. That structure explains why analysts can support the strategic logic while assigning different values to dilution, leverage and integration execution.

Stock remains above yearly low

C. H. Robinson Worldwide was last at USD 135.18 on Nasdaq on October 7, 2026, with a 52-week range of USD 123.64 to USD 210.33. Its market capitalization stood at USD 15.9 billion, while the Q2 diluted EPS figure was USD 1.61 versus USD 1.53 consensus, according to MarketBeat.

More news and analysis on C. H. Robinson Worldwide stock